News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
|
|
- Reginald Glenn
- 5 years ago
- Views:
Transcription
1 News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
2 Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and travel grants: Sanofi-Aventis, Merck
3 The cancer-immunity cycle DS. Chen and I. Mellman. Oncology Meets Immunology: The Cancer- Immunity Cycle. Immunity 39, July 25, 2013
4 The cancer-immunity cycle DS. Chen and I. Mellman. Oncology Meets Immunology: The Cancer- Immunity Cycle. Immunity 39, July 25, 2013
5 # Abstracts and presentations at ASCO Immunotherapy PD-1/ PD-L1
6 # clinical trials clinicaltrials.gov with agents blocking PD-1/PD-L1 pathway keywords PD-1 or PD-L1
7 Clinical trials using agents targeting PD1 pathway Tumor Immunology: Basic Biology for Clinical Practice. Vamsidhar Velcheti
8 ASCO 2016 focus on PD-1 axis inhibitor therapy and on biomarker studies An insight on the complexities and contradictions surrounding PD-L1 as biomarker Updated follow-up data on long-term outcome of PD-1 blocking agents lessons to be learnt Which other (molecular subtypes of) cancers appear to have great benefit of checkpoint blockade
9 Question 1 PD-L1 IHC at present is not useful as sole complementary diagnostic biomarker and should be abandoned for assessment of suitability to anti-pd-1/pd-l1 therapy A. Disagree, useful for selection of NSLC pts B. Disagree, useful for selection of melanoma pts B. Disagree, useful for selection of bladder cancer pts C. Agree, more research is needed
10 Complexities in the use of PD-L1 in clinical trials Diagnostic PD-L1 immunohistochemistry assays may vary, with each pharmaceutical company utilizing its own test PD-L1 positivity, generally considered PD-L1 expression on tumor cells Different thresholds of PD-L1 positivity, ranging between 1 and 50 percent Considerable PD-L1 heterogeneity within tumors and between tumor sites, which may not be accurately accounted for in small tumor biopsy Gaule P et al. Jama Oncol 2016 specimens Where Does the Truth Lie in Immune Biomarker Development? Suzanne Topalian Primary melanoma, nodular subtype. 10% of tumor cells express PD-L1 Tumour cells Taube et al. Sci Transl Med 2012 Melanoma cells Macrophages Lymphocytes Lymphs
11 Complexity of the PD-L1 biomarker (2) Topalian et al. NEJM 2012 Variable expression of PD-L1 among multiple melanoma lesions from individual patients receiving anti-pd-1 therapy PD-L1+ tumour >5% tumor cells with cell surface PD-L1 expression by IHC PD-L1+ patient patient in whom any tumor is PD-L1+ Where Does the Truth Lie in Immune Biomarker Development? Suzanne Topalian
12 Atezolizumab in lung and bladder PD-L1 agent PD-L1 Ab negative low high highest IC/TC Atezolizumab (Roche) SP142 (Ventana) IC0 (<1%) IC1 ( 1% but <5%) IC2/3 ( 5%) IC3 ( 10%) TC0 (<1%) TC1 ( 1% but <5%) TC2/3 ( 5%) TC3( 50%) POPLAR phase II 7,8% 18,3% 22,3% 37,5% TC and IC ORR ImVigor210 Phase II 2 nd line ImVigor210 Platinum-unfit 8% 10% 26% N/A IC only 21% 23% 28% N/A IC only IC/TC compartments distinct, in particular the IC3 and TC3 Fehrenbacher et al. POPLAR. The Lancet Vol387 April 30, 2016 Rosenberg et al. NCT The Lancet Vol 387 May 7, 2016
13 FDA approvals for checkpoint blockers and PD-L1 IHC tests Where Does the Truth Lie in Immune Biomarker Development? Suzanne Topalian
14 New regulatory terminology companion vs complementary diagnostic Companion diagnostic: provides information that is essential for the safe and effective use of a corresponding drug or biological product Example: PD-L1 IHC 22C3 for pembrolizumab in NSCLC Complementary diagnostic: not required, but aids risk/benefit assessment for drug use in individual patients Example: PD-L1 IHC 28-8 for nivolumab in NSCLC and melanoma; PD-L1 IHC SP142 for atezolizumab in bladder cancer Where Does the Truth Lie in Immune Biomarker Development? Suzanne Topalian
15 Question 2 If possible I would treat all metastatic melanoma patients in the first line with the combination of a CTLA-4 and a PD-1 pathway inhibitor A. Yes (if performance status is 0-1) B. No, only BRAF wt patients B. No, only PD-L1 IHC low C. No, only PD-L1 IHC high
16 CheckMate-067 CheckMate-067 phase III updated results of nivolumab combined with ipilimumab. Jedd Wolchok
17 CheckMate-067: PFS by Tumour PD-L1 Expression CheckMate-067 phase III updated results of nivolumab combined with ipilimumab. Jedd Wolchok
18 Immune Response is Dynamic: Many Signals evolve over time to regulate T Cell responses Immune-editing MHC PD-1/PD-L1 As Predictive Biomarkers: Where do we stand. Padmanee Sharma
19 Considering PD-L1 expression as a predictive biomarker of clinical response Major Considerations Tumor PD-L1 expression may change over time and after systemic and local therapies; thus, archived tumor samples may not be ideal in determining current PD-L1 tumor status. PD-L1 expression at a single time point may not reflect an evolving immune response in the blood or tumour microenvironment Responses to PD-1 axis inhibitor therapy have been seen in 5 to 20 percent of patients with reported PD-L1- negative tumors across trials. Higher mutational load associates with increased clinical benefit to checkpoint inhibitors (CTLA-4/PD-1) Integration of multiple biological components (CD8 TIL, PD-L1 expression, IFNγ-signature genes, mutational load etc) Rooney et al. Cell 2015 PD-1/PD-L1 As Predictive Biomarkers: Where do we stand. Padmanee Sharma Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-pd- 1/PD-L1. Douglas Johnson
20 Schumacher & Blank 2015
21 ASCO 2016 focus on PD-1 axis inhibitor therapy and on biomarker studies An insight on the complexities and contradictions surrounding PD-L1 as biomarker Updated follow-up data on long-term outcome of PD-1 blocking agents lessons to be learnt Which other (molecular subtypes of) cancers appear to have great benefit of checkpoint blockade
22 Keynote-001 phase Ib. Three-year survival update. Caroline Robert Keynote-001: Overall Survival
23 Keynote-001: Progression-free Survival Keynote-001 phase Ib. Three-year survival update. Caroline Robert
24 Complete responders (Pembro% for observation, N=61) Keynote-001 phase Ib. Three-year survival update. Caroline Robert
25 Complete responders (Pembro% for observation, N=61) Keynote-001 phase Ib. Three-year survival update. Caroline Robert
26 Complete responders (Pembro% for observation, N=61) Keynote-001 phase Ib. Three-year survival update. Caroline Robert
27 Complete responders (Pembro% for observation, N=61) Keynote-001 phase Ib. Three-year survival update. Caroline Robert
28 CheckMate-067 CheckMate-067 phase III updated results of nivolumab combined with ipilimumab. Jedd Wolchok
29 CheckMate-067: PFS (ITT) CheckMate-067 phase III updated results of nivolumab combined with ipilimumab. Jedd Wolchok
30 CheckMate-067: CheckMate-067 phase III updated results of nivolumab combined with ipilimumab. Jedd Wolchok
31 ASCO 2016 focus on PD-1 axis inhibitor therapy and on biomarker studies An insight on the complexities and contradictions surrounding PD-L1 as biomarker Updated follow-up data on long-term outcome of PD-1 blocking agents lessons to be learnt Which other (molecular subtypes of) cancers appear to have great benefit of checkpoint blockade
32 PD-1 Blockade in non-crc MMR Deficient Cancer Schumacher TN, Schreiber RD; Science 2015 PD-1 Blockade In MMR deficient cancer. Luis Diaz.
33 PD-1 Blockade in non-crc MMR Deficient Cancer Mismatch repair deficiency refers to deficiency in proteins responsible for DNA mismatch repair: MSH2, MSH6, MLH1, PMS2 Germline (Lynch syndrome) and/or sporadic mutations Epigenetic silencing (MLH1 hypermethylation) MMR deficiency leads to the microsatellite instability-high (MSI-H) phenotype MMR deficient tumors harbor thousands of mutations which could potentially be recognized by the immune system PD-1 Blockade In MMR deficient cancer. Luis Diaz.
34 Baseline characteristics non-crc MMR deficient cohort Characteristics MMR-deficient non CRC n=30 Median Age (range) years 56 (36-92) Gender-female no. (%) 14 (47) ECOG PS-zero 6 (20) Primary location endometrial ampullary biliary pancreatic small bowel gastric other (prostate/thyroid/sarcoma) 9 (30) 7 (23) 4 (13) 4 (13) 3 (10) 3 (10) Metastatic 30 (100) Liver metastasis 16 (53) Median Prior Regiments 2 Germline mutation/lynch Syndrome 5 (17) PD-1 Blockade In MMR deficient cancer. Luis Diaz.
35 Objective Responses non-crc MMR deficient cohort Type of Response Complete Response 9 (30) Partial Response 7 (23) Stable Disease (wk 12) 5 (17) Progressive disease 7 (23) Not Evaluable 2 (7) MMR-deficient non CRC n=30 Objective Response Rate (%) [95% CI] Disease Control Rate (%) [95% CI] Median follow up -months (53) [36-70] 21 (70) [52-83] PD-1 Blockade In MMR deficient cancer. Luis Diaz.
36 Immunotherapy in Merkel Cell Carcinoma Aggressive skin cancer associated with poor survival outcome in patients with metastatic disease MCC polyomavirus (MCPyV) Exposure UV light Immunosuppression Advanced age 1 st line CT 2 nd line no SOC (following CT) Avelumab (MSB C; anti-pd-l1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. Howard Kaufman.
37 Immunotherapy in Merkel Cell Carcinoma Rationale for immunotherapy Viral-mediated disease MCPyV-specific T cell dysfunction Checkpoints (PD-1 and Tim-3) expressed by MCC tumor cells and by adjacent immune cell infiltrates Improved PFS with high serum Ab titers against MCPyV CD8 T cells increase with larger tumor burden Improved OS with high CD3+, CD8+ TILs MCPyV-negative tumours have higher mutation and neo-antigen burden Avelumab (MSB C; anti-pd-l1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. Howard Kaufman.
38 Baseline characteristics of MCC patients treated with PD-1 pathway inhibitors Characteristics 1 st line (n=26) PD-1 Phase II noncontrolled multicenter US trial 2 nd line (n=88) PD-L1 Phase II noncontrolled multicenter international Pembrolizumab Avelumab Age, median (range) 68 [57-91) 72.5 [33-88] Sex, female (%) 10 (38) 23 [26] Disease stage, no. (%) IIIB IV 2 (8) 24 (92) 0 88 (100) Virus-positive tumours, no. (%) 17 (65%) 46 (52.3) ECOG PS 0 1 N/A N/A 49 (55.7) 39 (44.3) PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. P.Nghiem et al. NEJM 2016 Avelumab (MSB C; anti-pd-l1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. Howard Kaufman.
39 Outcome of MCC patients treated with PD-1 pathway inhibitors Overall response 1 st line (n=26) 2 nd line (n=88) Complete Response, no. (%) 4 (16) 9 (9.1) Partial Response, no. (%) 10 (40) 20 (22.7) Stable Disease, no. (%) 1 (4) 9 (10.2) Progressive Disease, no. (%) 9 (36) 32 (36.4) Non-evaluable 1 (4) 18 (20.5) Objective response rate (%) PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. P.Nghiem et al. NEJM 2016 Avelumab (MSB C; anti-pd-l1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. Howard Kaufman.
40 Avelumab in MCC: Tumour regression First-line pembrolizumab Second-line avelumab PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. P.Nghiem et al. NEJM 2016 Avelumab (MSB C; anti-pd-l1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. Howard Kaufman.
41 Other news from ASCO Promising early results of PD-1 checkpoint axis inhibition TNBC Keynote-012 (Nanda JCO July 2016); Atezolizumab phase I (AACR 2016); Avelumab Javelin phase I Ongoing Keynote-086, Impassion130, Keynote-119, Keynote-173 Haematological cancers
42 Take Home Message PD-1/PD-L1 checkpoint inhibitors continue to dominate presentations at ASCO PD-L1 is a dynamic biomarker and in particular negative results should be interpreted with caution, in particular when used as sole biomarker (even for NSCLC with 22C3 companion diagnostic) A plethora of combination trial with CTLA-4 and co-stimulatory pathways are expected in 2017 Thank you for your attention
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationTHE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationInmunoterapia en tumores digestivos no colorrectales
Inmunoterapia en tumores digestivos no colorrectales Santander, 13 de Julio del 2017 Maria Alsina, MD PhD Hospital Universitari Vall d Hebron Outline Introduction Hepatocarcinoma Pancreatic Cancer Gastric
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationImmunoterapia e farmaci innovativi
Immunoterapia e farmaci innovativi Emilio Bria Oncologia Medica, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Padova, 29 Ottobre 2015 Disclosures Advisory
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Royal Marsden Hospital ESMO Colorectal Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role Servier, Celgene, BMS, Five
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationImmunotherapy in breast cancer. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy
Immunotherapy in breast cancer Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy Outline Rational for immune-based therapy in breast cancer Immunogenic chemotherapy Targeting immune
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationSpecial situations: Patients with liver metastasis or liver primary tumor. Erika Martinelli, MD PhD Medical Oncologist
Special situations: Patients with liver metastasis or liver primary tumor Erika Martinelli, MD PhD Medical Oncologist Outline: Liver (anatomy, basic functions) Liver Immuno-landscape Immuno-landscape in
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationMaster Protocols FDA Oncology Experience
Master Protocols FDA Oncology Experience Rajeshwari Sridhara, Ph.D. Director, Division of Biometrics V Center for Drug Evaluation and Research, USFDA Outline Regulations FDA Experience with Basket, Umbrella
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationStatistical approach to immunotherapy trials
Statistical approach to immunotherapy trials Urania Dafni National and Kapodistrian University of Athens Frontier Science Foundation-Hellas SAMO Interdisciplinary Workshop on Immunotherapy Lucerne Suisse
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationInmunoterapia en el carcinoma de Células de Merkel. Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona
Inmunoterapia en el carcinoma de Células de Merkel Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Epidemiology Merkel cell carcinoma is an uncommon neuroendocrine carcinoma that mostly arises
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationDaniel Lieber, Ph.D. Senior Scientist, Computational Biology Foundation Medicine, Cambridge, MA. AACR 2017: Clinical Biomarkers April 3, 2017
Validation & clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Daniel Lieber, Ph.D. Senior Scientist, Computational
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationRoche Pharma Day 2015
Roche Pharma Day 2015 Molecular Information Garret Hampton VP, Oncology Biomarker Development Pharmaceuticals Division Personalized healthcare A cornerstone of the Genentech / Roche strategy Diagnostics
More informationLights and sheds of early approval of new drugs in clinical routine. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy
Lights and sheds of early approval of new drugs in clinical routine Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy RCT 5-10% pts «real» patients are here Clin. Pharm. Ther. 2012
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationApproval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology
Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Steven Lemery, MD, MHS Associate Director, DOP2 Traditional development paradigm Based on tumor
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationLung cancer PD-L1 testing clinical impact
Lung cancer PD-L1 testing clinical impact Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP Immune therapy with checkpoint-inhibitors
More informationIl Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali
Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures
More informationEl contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationVernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More information